Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Posted by Brian Himes on Aug 7th, 2026

Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) has been assigned an average rating of “Moderate Buy” from the fourteen analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and thirteen have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $45.80.

Several equities research analysts have weighed in on AVTX shares. Citizens Jmp dropped their price objective on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a report on Thursday, May 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Avalo Therapeutics in a research note on Friday, July 24th. Mizuho boosted their target price on Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. HC Wainwright decreased their target price on Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Avalo Therapeutics in a research note on Wednesday, May 6th.

Get Our Latest Stock Analysis on Avalo Therapeutics

Insider Buying and Selling

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total value of $26,100.00. Following the completion of the transaction, the insider directly owned 51,776 shares in the company, valued at approximately $931,968. This represents a 2.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.46% of the company’s stock.

Institutional Investors Weigh In On Avalo Therapeutics

A number of large investors have recently modified their holdings of AVTX. Bank of New York Mellon Corp bought a new position in Avalo Therapeutics in the second quarter worth about $1,897,000. Seven Fleet Capital Management LP lifted its holdings in Avalo Therapeutics by 806.0% in the first quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock worth $8,568,000 after buying an additional 510,540 shares during the period. DV Trading LLC bought a new stake in Avalo Therapeutics during the 1st quarter valued at approximately $5,376,000. Glenmede Trust Co. NA boosted its position in Avalo Therapeutics by 25.8% during the 1st quarter. Glenmede Trust Co. NA now owns 25,730 shares of the company’s stock valued at $384,000 after acquiring an additional 5,280 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Avalo Therapeutics by 3.5% during the 1st quarter. Bank of America Corp DE now owns 643,000 shares of the company’s stock worth $9,600,000 after acquiring an additional 21,650 shares during the period. Institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Trading Down 0.7%

Shares of NASDAQ:AVTX opened at $18.70 on Friday. The company has a 50-day moving average price of $17.22 and a 200-day moving average price of $16.27. The company has a market cap of $989.23 million, a price-to-earnings ratio of -3.42 and a beta of 0.80. Avalo Therapeutics has a 12 month low of $8.01 and a 12 month high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.25). As a group, research analysts forecast that Avalo Therapeutics will post -2.58 EPS for the current fiscal year.

Avalo Therapeutics Company Profile

(Get Free Report)

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.